drugset / Trial / NCT05668884
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
In this phase 2 study, the investigators aim to evaluate the effects and safety of combined therapy using oxaliplatin and gemcitabine chemotherapy, Donafenib and Tislelizumab for patients with advanced biliary tract carcinoma.
Timeline
- Start
- 2022-10-18
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |